Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.7 EUR | -1.21% | -1.21% | -14.16% |
Jan. 30 | Nanobiotix Gets $20 Million Milestone Payment in Phase 3 Trial for Potential Head, Neck Cancer Drug | MT |
Jan. 30 | Nanobiotix: targets achieved for NANORAY-312 | CF |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-14.16% | 294M | |
+9.30% | 45.97B | |
+52.73% | 43.93B | |
+7.15% | 42.34B | |
-8.78% | 28.27B | |
+18.68% | 27.18B | |
-21.92% | 19.44B | |
+14.62% | 13.83B | |
+31.85% | 12.4B | |
+4.47% | 11.45B |
- Stock
- Equities
- Stock Nanobiotix - Euronext Paris
- News Nanobiotix
- Nanobiotix : Cancer Combo Therapy Shrinks Tumor in Early-Stage Study